Azeliragon

Steve Holcombe transitioned from telecom to biotech back when vTv Therapeutics Inc (NASDAQ: VTVT) was just a startup. Now, 18 years in, he’s finally seeing the fruits of his labor. “We’re getting close to the finish line,” Holcombe, the CEO of VTV, told Benzinga. “We...

Shares of clinical-stage pharmaceutical company vTv Therapeutics Inc. (NASDAQ: VTVT) surged 50 percent Wednesday morning. What Happened The company is engaged in the research and development of treatments for Alzheimer’s disease and diabetes. This week, it announced the delivery of an...

HC Wainwright has started coverage of vTv Therapeutics Inc (NASDAQ: VTVT) with a Buy rating and $13 price target on the potential success of its three late-stage drugs, especially the two diabetic compounds. In fact, the brokerage expects the diabetes compounds to be more likely to move the stock...